Recent technical advances in conventional transarterial chemoembolization for hepatocellular carcinoma in Japan

Higashihara, Hiroki; Ono, Yoshio; Tanaka, Kaishu; Tomotake, Kosuke; Tomiyama, Noriyuki

doi:10.18528/ijgii210042

Cited by 2 publications

(4 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This technique provides several advantages. Firstly, TACE has been shown to improve overall survival in the treatment of unresectable intermediate HCC [ 2 , 3 , 5 , 28 ]. However, local recurrence or incomplete treatment is common, especially in larger tumors [ 29 ].…”

Section: Discussionmentioning

confidence: 99%

“…However, local recurrence or incomplete treatment is common, especially in larger tumors [ 29 ]. Conventional TACE was initially performed using lipiodol-mixed lyophilized formulations of cytotoxic agents, followed by embolic agents [ 12 , 28 ]. Numerous cytotoxic agents have been used in cTACE, but the most ubiquitous combination was doxorubicin, mitomycin, and cisplatin [ 12 , 30 ].…”

Section: Discussionmentioning

confidence: 99%

“…The mixture itself was administered until vascular stasis. In cTACE studies, it has been demonstrated that without an embolic agent, there is a systemic escape of the cytotoxic agents administered with lipiodol [ 28 , 63 , 64 ]. It is unclear whether the high systemic concentrations could have been lowered through the use of an embolic material.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Drug-Eluting Embolic Loaded with Tyrosine Kinase Inhibitor Targeted Therapies for Transarterial Chemoembolization in a VX2 Model

Abi-Jaoudeh

Sadeghi

Javan

et al. 2023

Cancers

View full text Add to dashboard Cite

Drug-eluting embolic transarterial chemoembolization (DEE-TACE) improves the overall survival of hepatocellular carcinoma (HCC), but the agents used are not tailored to HCC. Our patented liposomal formulation enables the loading and elution of targeted therapies onto DEEs. This study aimed to establish the safety, feasibility, and pharmacokinetics of sorafenib or regorafenib DEE-TACE in a VX2 model. DEE-TACE was performed in VX2 hepatic tumors in a selective manner until stasis using liposomal sorafenib- or regorafenib-loaded DEEs. The animals were euthanized at 1, 24, and 72 h timepoints post embolization. Blood samples were taken for pharmacokinetics at 5 and 20 min and at 1, 24, and 72 h. Measurements of sorafenib or regorafenib were performed in all tissue samples on explanted hepatic tissue using the same mass spectrometry method. Histopathological examinations were carried out on tumor tissues and non-embolized hepatic specimens. DEE-TACE was performed on 23 rabbits. The plasma concentrations of sorafenib and regorafenib were statistically significantly several folds lower than the embolized liver at all examined timepoints. This study demonstrates the feasibility of loading sorafenib or regorafenib onto commercially available DEEs for use in TACE. The drugs eluted locally without release into systemic circulation.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Drug-Eluting Embolic Loaded with Tyrosine Kinase Inhibitor Targeted Therapies for Transarterial Chemoembolization in a VX2 Model

Abi-Jaoudeh

Sadeghi

Javan

et al. 2023

Cancers

View full text Add to dashboard Cite

show abstract

“…Among them, advancements in catheter technology are considered as a crucial determinant of treatment success. Of particular significance is the role of microcatheter in enhancing TACE outcomes, as they have undergone significant advancements in Japan [19].…”

Section: Innovative Techniques Employed During the Implementation Of ...mentioning

confidence: 99%

Effective Utilization of Conventional Transarterial Chemoembolization and Drug-eluting Bead Transarterial Chemoembolization in Hepatocellular Carcinoma: A Guide to Proper Usage

Higashihara,

Kimura,

Ono

et al. 2023

Interventional Radiology

Self Cite

View full text Add to dashboard Cite

Transarterial chemoembolization is still an effective treatment option for hepatocellular carcinoma worldwide and is categorized into conventional transarterial chemoembolization with ethiodized oil transarterial chemoembolization and transarterial chemoembolization with drug-eluting spherical material transarterial chemoembolization. Several randomized controlled trials conducted in Europe have shown the equivalent efficacy of ethiodized oil transarterial chemoembolization and drug-eluting spherical material transarterial chemoembolization. However, a recent randomized controlled trials in Japan established the superiority of ethiodized oil transarterial chemoembolization in terms of complete response rates although higher liver toxicity for ethiodized oil transarterial chemoembolization. Nevertheless, the survival advantage of ethiodized oil transarterial chemoembolization is yet to be substantiated. The adverse effects of drug-eluting spherical material transarterial chemoembolization are milder than those of ethiodized oil transarterial chemoembolization, rendering drug-eluting spherical material transarterial chemoembolization an advantageous option for patients with bilobar tumors and impaired liver function/performance status. This article aims to provide an overview of these embolization techniques and a review of recent literature.

show abstract

Recent technical advances in conventional transarterial chemoembolization for hepatocellular carcinoma in Japan

Cited by 2 publications

References 53 publications

Drug-Eluting Embolic Loaded with Tyrosine Kinase Inhibitor Targeted Therapies for Transarterial Chemoembolization in a VX2 Model

Drug-Eluting Embolic Loaded with Tyrosine Kinase Inhibitor Targeted Therapies for Transarterial Chemoembolization in a VX2 Model

Effective Utilization of Conventional Transarterial Chemoembolization and Drug-eluting Bead Transarterial Chemoembolization in Hepatocellular Carcinoma: A Guide to Proper Usage

Contact Info

Product

Resources

About